Tabacco Use DisorderVICTORNCT07050862
Personalized Brain Stimulation to Help Veterans Quit Smoking
A study testing Transcranial Magnetic Stimulation and Personalized-image-guided and E-field-modeling dose rTMS (precision TMS) in people with Tabacco Use Disorder and rTMS, run by VA Office of Research and Development at 1 site in United States.
Trial summary
Cigarette smoking is a significant public health concern for Veterans. Encouraging smoking cessation continues to be a top priority for the Veterans' Administration as Veterans who use tobacco experience negative health effects, including cancer, heart disease, and mental disorders. Read more about this study
- Who is it for?
- Ages 18 to 70 years
- Conditions the study is for
- Tabacco Use Disorder, rTMS
- What is being tested?
- Transcranial Magnetic Stimulation and Personalized-image-guided and E-field-modeling dose rTMS (precision TMS)
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 56 participants
- Where
- 1 siteUnited States
- Study dates
- 1 Jul 2026to 31 Aug 2030
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 70 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Veteran
- Individuals who smoke 10 or more cigarettes per day and have a CO level > 10 ppm indicative of recent smoking
- Those who have not received substance abuse treatment within the previous 30 days
- Those who have been stable on psychotropic medications for at least three months
- For females, those who test non-pregnant and use adequate birth control
- Those who are willing to provide informed consent
- Those who can comply with protocol requirements and likely complete all study procedures
- Those who are motivated to quit smoking (based on responses of "very likely" or "somewhat likely" in the motivation questionnaire
Who cannot join
- Current moderate to severe substance use of any psychoactive substances other than nicotine or caffeine, as defined by DSM-V criteria
- Contraindications to MRI (e.g., metal in the skull, orbital or intracranial cavity, or claustrophobia)
- Contraindications to rTMS (history of a seizure or epilepsy)
- A history of autoimmune, endocrine, viral, or vascular disorders affecting the brain
- History or MRI evidence of neurological disorder that would lead to local or diffuse brain lesions or significant physical impairment
- Unstable cardiac disease, uncontrolled hypertension, severe renal or liver insufficiency, or sleep apnea
Show all 10Show fewer
- Major Axis I disorders diagnosed according to DSM-V criteria, such as bipolar affective disorder, schizophrenia, dementia, or major depression
- Regarding the Veteran population, the investigators will enroll smokers who have PTSD
- Current use of other forms of nicotine delivery, such as nicotine patches or electronic cigarettes
- Currently prescribed bupropion and/or varenicline
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
Ralph H. Johnson VA Medical Center, Charleston, SC
Charleston, South Carolina, 29401-5703
R. Amanda C LaRue, PhD, (843) 789-6707, Rutha.Larue@va.gov
Sarah A Jackson, BA MA, (843) 789-6700, sarah.jackson@va.gov
About this study
Official title: Circuity-guided Repetitive Transcranial Magnetic Stimulation (rTMS) for Tobacco Use in Veterans: A Comparison of Insula-rTMS and Prefrontal-rTMS
Cigarette smoking is a significant public health concern for Veterans. Encouraging smoking cessation continues to be a top priority for the Veterans' Administration as Veterans who use tobacco experience negative health effects, including cancer, heart disease, and mental disorders. Despite the efficacy of current evidence-based pharmacotherapies and psychotherapies for smoking cessation, alternative treatments are critically needed. Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive form of brain stimulation, US FDA-approved for smoking cessation. In this protocol, the investigators propose comparing the two rTMS protocols (standard TMS vs. precision TMS) to find a better treatment parameter for smoking cessation in Veterans. Identifying an efficacious rTMS protocol would benefit Veterans who want to quit smoking.
Read the detailed description
Cigarette smoking rates are high, and quitting rates are lower in the Veteran population in the United States compared to the nonveteran population. In addition, Veterans report being more likely to have smoking- related illnesses and morbidity. Despite the efficacy of current evidence-based pharmacotherapies and psychotherapies for smoking cessation, alternative treatments are critically needed. Repetitive transcranial magnetic stimulation (rTMS), has already displayed remarkable potential for producing novel, non- pharmacological interventions for neuropsychiatric disorders, including tobacco use disorder (TUD). The group's studies demonstrate that 10 Hz rTMS over the left dorsolateral prefrontal cortex (DLPFC) reduced cue craving and cigarette consumption and increased quit rate. Instead of stimulating the superficial cortex, deep TMS (DTMS) has been permitted to target deep brain structures such as the insula. DTMS has also been approved to reduce cigarette consumption and increase quit rate and was FDA-approved as a treatment option for TUD. Neuroimaging techniques such as functional magnetic resonance imaging (fMRI) have provided insight into the neurocircuitry of TUD and its therapeutic effect for smoking cessation. Recently, the investigators' team completed an image-guided randomized controlled trial (RCT) study to compare 10 Hz rTMS over the left DLPFC to 1 Hz over the medial orbitofrontal cortex (mOFC) and sham in healthy smokers. The results showed that 10 Hz over DLPFC rTMS reduced cigarette consumption more than 1 Hz mOFC and sham. In addition, 10 Hz DLPFC rTMS increased brain activity in DLPFC and decreased brain activity in mOFC. The findings suggested that the effect of rTMS depended on the different brain regions of stimulation. To date, the efficacy of rTMS for smoking cessation has not yet been evaluated in Veterans. In this protocol, the investigators propose comparing the two rTMS protocols (DTMS vs. image-guided TMS) to find a better treatment parameter for smoking cessation in Veterans. Targeting two candidate brain regions (DLPFC vs. insula) with two different TMS treatment parameters will be performed. This application aims to identify a better rTMS treatment for smoking cessation and further develop a circuit-based precision rTMS therapy for TUDs in Veterans. The investigators hypothesize that image-guided DLPFC TMS (precision TMS) treatment will produce superior effects than insula DTMS (standard TMS) in reducing cigarette consumption. The investigators will also determine that image-guided DLPFC increases the connectivity between DLPFC, mOFC, and nucleus accumbens (NAc). In the 4-year study, the investigators will recruit 56 treatment-seeking TUDs. Participants will be randomized into two groups: The first arm is 10Hz rTMS (1800 pulses/session) over the bilateral insula with FDA-cleared DTMS (H4-coil). The other arm is image-targeted 10 Hz rTMS over the left DLPFC with figure 8 coil (3000 pulses/session). Both rTMS treatments will include 15 daily rTMS treatments for 3 weeks and 3 weeks of once- weekly rTMS. The primary endpoint will be the reduction of cigarette consumption at the end of the 3-week rTMS treatment. Aim 1: Determine whether precision image-guided TMS over the left DLPFC results in a larger reduction in cigarette consumption compared to standard DTMS targeting the insula. The primary outcome will be cigarettes per day during the treatment course. The investigators will compare the reduction of cigarette compensation between two treatment groups at the end of the 3-week rTMS treatment. Aim 2: Determine whether precision image-guided TMS increases activity in the DLPFC and modulates connectivity among the DLPFC, mOFC, and NAc and whether standard DTMS increases activity in the insula, [mOFC] and modulates connectivity among the insula, [mOFC] and NAc. The investigators will compare precision TMS to standard TMS using whole-brain imaging and network connectivity analyses. Aim 3 (exploratory): Determine whether the reductions in cigarette consumption are associated with the modulated connectivity among DLPFC, [mOFC] and NAc after precision TMS and the modulated connectivity among insula, [mOFC] and NAc after standard TMS. The investigators will test if brain connectivity can be used to predict the clinical effects of rTMS.
- Conditions
- Tabacco Use Disorder, rTMS
- Being tested
- Transcranial Magnetic Stimulation, Personalized-image-guided and E-field-modeling dose rTMS (precision TMS)
- Keywords
- Tabacco use disorder, Veterans, Transcranial Magnetic Stimulation, Smoking Cessation
- Medical subject headings
- Smoking Cessation
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Transcranial Magnetic StimulationDevice
Also called Deep TMS, Standard rTMS
The first group will receive 10 Hz DTMS (standard TMS) with a protocol of 3 seconds on, 15 seconds off, and a total of 1800 pulses/session, lasting 18 minutes, targeting the bilateral insula and lateral prefrontal cortex.
Personalized-image-guided and E-field-modeling dose rTMS (precision TMS)Device
With a protocol of 5 seconds on, 10 seconds off, and a total of 3000 pulses/session, lasting 15 minutes, targeting the left DLPFC.
| Study group | Role | What they receive |
|---|---|---|
| Deep rTMS | Active comparator | The first group will receive 10 Hz DTMS (standard TMS) with a protocol of 3 seconds on, 15 seconds off, and a total of 1800 pulses/session, lasting 18 minutes, targeting the bilateral insula and lateral prefrontal cortex. Receives: Device: Transcranial Magnetic Stimulation |
| Precision TMS | Experimental | The other group will receive 10 Hz personalized-image-guided and Efield-modeling dose rTMS (precision TMS) with a protocol of 5 seconds on, 10 seconds off, and a total of 3000 pulses/session, lasting 15 minutes, targeting the left dorsolateral prefrontal cortex (DLPFC). Receives: Device: Personalized-image-guided and E-field-modeling dose rTMS (precision TMS) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Cigarettes per day (CPD)
The investigators will compare the reduction of cigarette consumption between the two treatment groups at the end of the 3-week Repetitive Transcranial Magnetic Stimulation (rTMS) treatment. A higher reduction of CPD means a better treatment result.
Measured: The cigarettes per day will be measured up to 3 weeks for the outcome 1
Brain Imaging Outcomes - Cue Craving Scans
Functional magnetic resonance imaging (fMRI) scans of all Veterans to look at brain function connectivity. The investigators will compare the changes of brain activity between two treatment conditions.
Measured: 3-weeks
Secondary outcomes (10)
7-day continuous quit rate (CQR)
Abstinence during a consecutive 7-day period in the treatment stage
Measured: 10 weeks
Likert Visual Analog Cue Craving Scale
Assess changes in subjective craving with each session. The visual analog cue craving scale from 0 to 7. 0 = minimum, 7 = maximum. A higher score means more craving (worse).
Measured: 10 weeks
Fagerstrom Test for Nicotine Dependence (FTND)
Standardized tool to assess intensity of physical addiction to nicotine.
Measured: 10 weeks
Minnesota Nicotine Withdrawal Scale-Revised
Self-report scale developed to evaluate the severity of nicotine withdrawal symptoms. self-report scale developed to evaluate the severity of nicotine withdrawal symptoms. It includes 15 items. Each item is from 0 to 4, total score, 0 = minimum, 60 = maximum. A higher score means worse.
Measured: 10 weeks
Questionnaire of Smoking Urges- Brief (QSU-B )
A brief 10-item scale assessing smoking urges. There are 10 questions. Each question can be rated from 1 to 7. Total score: 10 is minimum, 70 is maximum. A higher score means worse.
Measured: 10 weeks
Cabry Oxy levels
0-6 ppm: no smoker, 7-19 ppm: light smoker; 20 or more ppm: heavy smoker.
Measured: 3-weeks
Biomarkers
Urine cotinine levels will be measured. Urine creatinine will also be measured for the correction of urine cotinine. Urine cotinine levels will be measured. Urine creatinine will also be measured for the correction of urine cotinine. A higher level is worse.
Measured: 10 weeks
PTSD Checklist for DSM-5
20 item self report measure to assess DSM-5 PTSD. It includes 20 items. Each item will rate from 0 to 4. Minimum = 0, Maximum = 80. A higher score means worse.
Measured: 10 week
Patient Health Questionnaire (PHQ-9),
PHQ-9 is a self-report that screens for depression and measures its severity.
Measured: 10-weeks
Generalized-Anxiety-Disorder (GAD- 7)
7 item scale that screens for and assess severity of GAD. There are 7 question in the scale. Each question can be 0 to 3. Minimum = 0, Maximum = 27. A higher scores mean worse.
Measured: 10 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Jul 2025
- Study start1 Jul 2026
- Primary completion30 Apr 2030 (estimated)
- Study completion31 Aug 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (3)Papers the sponsor has linked to this study.
- Other trials for Tabacco Use DisorderStudies of the same condition, open and under way.
- More trials run by VA Office of Research and DevelopmentThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Standard rTMS vs Precision rTMS
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 56 participants (estimated)
Sponsor and investigators
- Lead sponsor
- VA Office of Research and Development
- Sponsor type
- US federal agency
- Responsible party
- Sponsor
- Investigators
- Xingbao Li, MD MS, Principal investigator, Ralph H. Johnson VA Medical Center, Charleston, SC
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07050862
- Sponsor's protocol ID
- NURA-005-24F
- Other IDs
- Pro00141919
- Acronym
- VICTOR
- Status last verified
- Jul 2026
- First submitted
- 15 May 2025
- Last updated
- 4 Aug 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
- Individual data sharing
- No
Publications
Li X, Hartwell KJ, Henderson S, Badran BW, Brady KT, George MS. Two weeks of image-guided left dorsolateral prefrontal cortex repetitive transcranial magnetic stimulation improves smoking cessation: A double-blind, sham-controlled, randomized clinical trial. Brain Stimul. 2020 Sep-Oct;13(5):1271-1279. doi: 10.1016/j.brs.2020.06.007. Epub 2020 Jun 10.
PubMed 32534252Li X, Hartwell KJ, Owens M, Lematty T, Borckardt JJ, Hanlon CA, Brady KT, George MS. Repetitive transcranial magnetic stimulation of the dorsolateral prefrontal cortex reduces nicotine cue craving. Biol Psychiatry. 2013 Apr 15;73(8):714-20. doi: 10.1016/j.biopsych.2013.01.003. Epub 2013 Feb 26.
PubMed 23485014Li X, Toll BA, Carpenter MJ, Nietert PJ, Dancy M, George MS. Repetitive Transcranial Magnetic Stimulation for Tobacco Treatment in Cancer Patients: A Preliminary Report of a One-Week Treatment. J Smok Cessat. 2022 Jul 11;2022:2617146. doi: 10.1155/2022/2617146. eCollection 2022.
PubMed 35909440
Study at a glance
From the registry record, last updated by the sponsor on 4 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Circuity-guided Repetitive Transcranial Magnetic Stimulation (rTMS) for Tobacco Use in Veterans: A Comparison of Insula-rTMS and Prefrontal-rTMS
- ClinicalTrials.gov ID
- NCT07050862
- Acronym / sponsor ID
- VICTOR / NURA-005-24F
- Conditions
- Tabacco Use Disorder, rTMS
- Keywords
- Tabacco use disorder, Veterans, Transcranial Magnetic Stimulation, Smoking Cessation
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 56 participants (estimated)
- Lead sponsor
- VA Office of Research and DevelopmentUS federal agency
- Study start
- 1 Jul 2026 (actual)
- Primary completion
- 30 Apr 2030 (estimated)
- Study completion
- 31 Aug 2030 (estimated)
- First posted
- 3 Jul 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Cigarette smoking is a significant public health concern for Veterans. Encouraging smoking cessation continues to be a top priority for the Veterans' Administration as Veterans who use tobacco experience negative health effects, including cancer, heart disease, and mental disorders. Despite the efficacy of current evidence-based pharmacotherapies and psychotherapies for smoking cessation, alternative treatments are critically needed. Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive form of brain stimulation, US FDA-approved for smoking cessation. In this protocol, the investigators propose comparing the two rTMS protocols (standard TMS vs. precision TMS) to find a better treatment parameter for smoking cessation in Veterans. Identifying an efficacious rTMS protocol would benefit Veterans who want to quit smoking.
Detailed description
Cigarette smoking rates are high, and quitting rates are lower in the Veteran population in the United States compared to the nonveteran population. In addition, Veterans report being more likely to have smoking- related illnesses and morbidity. Despite the efficacy of current evidence-based pharmacotherapies and psychotherapies for smoking cessation, alternative treatments are critically needed. Repetitive transcranial magnetic stimulation (rTMS), has already displayed remarkable potential for producing novel, non- pharmacological interventions for neuropsychiatric disorders, including tobacco use disorder (TUD). The group's studies demonstrate that 10 Hz rTMS over the left dorsolateral prefrontal cortex (DLPFC) reduced cue craving and cigarette consumption and increased quit rate. Instead of stimulating the superficial cortex, deep TMS (DTMS) has been permitted to target deep brain structures such as the insula. DTMS has also been approved to reduce cigarette consumption and increase quit rate and was FDA-approved as a treatment option for TUD. Neuroimaging techniques such as functional magnetic resonance imaging (fMRI) have provided insight into the neurocircuitry of TUD and its therapeutic effect for smoking cessation. Recently, the investigators' team completed an image-guided randomized controlled trial (RCT) study to compare 10 Hz rTMS over the left DLPFC to 1 Hz over the medial orbitofrontal cortex (mOFC) and sham in healthy smokers. The results showed that 10 Hz over DLPFC rTMS reduced cigarette consumption more than 1 Hz mOFC and sham. In addition, 10 Hz DLPFC rTMS increased brain activity in DLPFC and decreased brain activity in mOFC. The findings suggested that the effect of rTMS depended on the different brain regions of stimulation. To date, the efficacy of rTMS for smoking cessation has not yet been evaluated in Veterans. In this protocol, the investigators propose comparing the two rTMS protocols (DTMS vs. image-guided TMS) to find a better treatment parameter for smoking cessation in Veterans. Targeting two candidate brain regions (DLPFC vs. insula) with two different TMS treatment parameters will be performed. This application aims to identify a better rTMS treatment for smoking cessation and further develop a circuit-based precision rTMS therapy for TUDs in Veterans. The investigators hypothesize that image-guided DLPFC TMS (precision TMS) treatment will produce superior effects than insula DTMS (standard TMS) in reducing cigarette consumption. The investigators will also determine that image-guided DLPFC increases the connectivity between DLPFC, mOFC, and nucleus accumbens (NAc). In the 4-year study, the investigators will recruit 56 treatment-seeking TUDs. Participants will be randomized into two groups: The first arm is 10Hz rTMS (1800 pulses/session) over the bilateral insula with FDA-cleared DTMS (H4-coil). The other arm is image-targeted 10 Hz rTMS over the left DLPFC with figure 8 coil (3000 pulses/session). Both rTMS treatments will include 15 daily rTMS treatments for 3 weeks and 3 weeks of once- weekly rTMS. The primary endpoint will be the reduction of cigarette consumption at the end of the 3-week rTMS treatment. Aim 1: Determine whether precision image-guided TMS over the left DLPFC results in a larger reduction in cigarette consumption compared to standard DTMS targeting the insula. The primary outcome will be cigarettes per day during the treatment course. The investigators will compare the reduction of cigarette compensation between two treatment groups at the end of the 3-week rTMS treatment. Aim 2: Determine whether precision image-guided TMS increases activity in the DLPFC and modulates connectivity among the DLPFC, mOFC, and NAc and whether standard DTMS increases activity in the insula, [mOFC] and modulates connectivity among the insula, [mOFC] and NAc. The investigators will compare precision TMS to standard TMS using whole-brain imaging and network connectivity analyses. Aim 3 (exploratory): Determine whether the reductions in cigarette consumption are associated with the modulated connectivity among DLPFC, [mOFC] and NAc after precision TMS and the modulated connectivity among insula, [mOFC] and NAc after standard TMS. The investigators will test if brain connectivity can be used to predict the clinical effects of rTMS.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
- Model description
- Standard rTMS vs Precision rTMS
| Arm | Type | Receives |
|---|---|---|
| Deep rTMS | Active comparator | Device: Transcranial Magnetic StimulationThe first group will receive 10 Hz DTMS (standard TMS) with a protocol of 3 seconds on, 15 seconds off, and a total of 1800 pulses/session, lasting 18 minutes, targeting the bilateral insula and lateral prefrontal cortex. |
| Precision TMS | Experimental | Device: Personalized-image-guided and E-field-modeling dose rTMS (precision TMS)The other group will receive 10 Hz personalized-image-guided and Efield-modeling dose rTMS (precision TMS) with a protocol of 5 seconds on, 10 seconds off, and a total of 3000 pulses/session, lasting 15 minutes, targeting the left dorsolateral prefrontal cortex (DLPFC). |
Who may qualify
- Ages
- 18 to 70 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (8 listed)
- Veteran
- Individuals who smoke 10 or more cigarettes per day and have a CO level > 10 ppm indicative of recent smoking
- Those who have not received substance abuse treatment within the previous 30 days
- Those who have been stable on psychotropic medications for at least three months
- For females, those who test non-pregnant and use adequate birth control
Key exclusion criteria (10 listed)
- Current moderate to severe substance use of any psychoactive substances other than nicotine or caffeine, as defined by DSM-V criteria
- Contraindications to MRI (e.g., metal in the skull, orbital or intracranial cavity, or claustrophobia)
- Contraindications to rTMS (history of a seizure or epilepsy)
- A history of autoimmune, endocrine, viral, or vascular disorders affecting the brain
- History or MRI evidence of neurological disorder that would lead to local or diffuse brain lesions or significant physical impairment
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Transcranial Magnetic StimulationAlso: Deep TMS, Standard rTMSThe first group will receive 10 Hz DTMS (standard TMS) with a protocol of 3 seconds on, 15 seconds off, and a total of 1800 pulses/session, lasting 18 minutes, targeting the bilateral insula and lateral prefrontal cortex. | Device | Deep rTMS |
| Personalized-image-guided and E-field-modeling dose rTMS (precision TMS)With a protocol of 5 seconds on, 10 seconds off, and a total of 3000 pulses/session, lasting 15 minutes, targeting the left DLPFC. | Device | Precision TMS |
Primary outcome
Cigarettes per day (CPD)
Time frame: The cigarettes per day will be measured up to 3 weeks for the outcome 1
The investigators will compare the reduction of cigarette consumption between the two treatment groups at the end of the 3-week Repetitive Transcranial Magnetic Stimulation (rTMS) treatment. A higher reduction of CPD means a better treatment result.
Brain Imaging Outcomes - Cue Craving Scans
Time frame: 3-weeks
Functional magnetic resonance imaging (fMRI) scans of all Veterans to look at brain function connectivity. The investigators will compare the changes of brain activity between two treatment conditions.
10 secondary outcomes
7-day continuous quit rate (CQR)
Time frame: 10 weeks
Likert Visual Analog Cue Craving Scale
Time frame: 10 weeks
Fagerstrom Test for Nicotine Dependence (FTND)
Time frame: 10 weeks
Minnesota Nicotine Withdrawal Scale-Revised
Time frame: 10 weeks
Questionnaire of Smoking Urges- Brief (QSU-B )
Time frame: 10 weeks
Cabry Oxy levels
Time frame: 3-weeks
Biomarkers
Time frame: 10 weeks
PTSD Checklist for DSM-5
Time frame: 10 week
Patient Health Questionnaire (PHQ-9),
Time frame: 10-weeks
Generalized-Anxiety-Disorder (GAD- 7)
Time frame: 10 weeks
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Aug 2026.
- Background: PubMed 32534252Li X, Hartwell KJ, Henderson S, Badran BW, Brady KT, George MS. Two weeks of image-guided left dorsolateral prefrontal cortex repetitive transcranial magnetic stimulation improves smoking cessation: A double-blind, sham-controlled, randomized clinical trial. Brain Stimul. 2020 Sep-Oct;13(5):1271-1279. doi: 10.1016/j.brs.2020.06.007. Epub 2020 Jun 10.
- Background: PubMed 23485014Li X, Hartwell KJ, Owens M, Lematty T, Borckardt JJ, Hanlon CA, Brady KT, George MS. Repetitive transcranial magnetic stimulation of the dorsolateral prefrontal cortex reduces nicotine cue craving. Biol Psychiatry. 2013 Apr 15;73(8):714-20. doi: 10.1016/j.biopsych.2013.01.003. Epub 2013 Feb 26.
- Background: PubMed 35909440Li X, Toll BA, Carpenter MJ, Nietert PJ, Dancy M, George MS. Repetitive Transcranial Magnetic Stimulation for Tobacco Treatment in Cancer Patients: A Preliminary Report of a One-Week Treatment. J Smok Cessat. 2022 Jul 11;2022:2617146. doi: 10.1155/2022/2617146. eCollection 2022.
- Individual participant dataSharing planned: No
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Xingbao Li, MD MS principal investigator
Ralph H. Johnson VA Medical Center, Charleston, SC
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Transcranial Magnetic Stimulation and Personalized-image-guided and E-field-modeling dose rTMS (precision TMS) in people with Tabacco Use Disorder and rTMS, run by VA Office of Research and Development at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 4 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Xingbao Li, MD MS ((843) 577-5011 ext. 205853, xingbao.li@va.gov), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Cigarettes per day (CPD) (time frame: The cigarettes per day will be measured up to 3 weeks for the outcome 1). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07050862, which also lists 3 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Aug 2026.